Kaleido Biosciences (KLDO) Competitors Add Compare Share Share Competitors Stock AnalysisChartCompetitorsSEC FilingsShort InterestTrendsBuy This Stock KLDO vs. AIXI, STIX, MTC, MTBLY, STRM, XTKG, SMSI, HKIT, MSGM, and NTCLShould you be buying Kaleido Biosciences stock or one of its competitors? The main competitors of Kaleido Biosciences include XIAO-I (AIXI), Semantix (STIX), MMTec (MTC), Moatable (MTBLY), Streamline Health Solutions (STRM), X3 (XTKG), Smith Micro Software (SMSI), Hitek Global (HKIT), Motorsport Games (MSGM), and NetClass Technology (NTCL). These companies are all part of the "computer software" industry. Kaleido Biosciences vs. Its Competitors XIAO-I Semantix MMTec Moatable Streamline Health Solutions X3 Smith Micro Software Hitek Global Motorsport Games NetClass Technology Kaleido Biosciences (NASDAQ:KLDO) and XIAO-I (NASDAQ:AIXI) are both small-cap computer software companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, profitability, media sentiment, risk, institutional ownership, earnings, dividends and analyst recommendations. Which has more volatility & risk, KLDO or AIXI? Kaleido Biosciences has a beta of -0.06, indicating that its stock price is 106% less volatile than the S&P 500. Comparatively, XIAO-I has a beta of 2.15, indicating that its stock price is 115% more volatile than the S&P 500. Which has stronger valuation and earnings, KLDO or AIXI? XIAO-I has higher revenue and earnings than Kaleido Biosciences. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKaleido Biosciences$1.10M0.00-$95.48M-$2.24N/AXIAO-I$70.31M0.37-$14.51MN/AN/A Do institutionals & insiders hold more shares of KLDO or AIXI? 81.6% of Kaleido Biosciences shares are owned by institutional investors. Comparatively, 4.0% of XIAO-I shares are owned by institutional investors. 9.0% of Kaleido Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Is KLDO or AIXI more profitable? Company Net Margins Return on Equity Return on Assets Kaleido BiosciencesN/A N/A N/A XIAO-I N/A N/A N/A Does the media prefer KLDO or AIXI? In the previous week, XIAO-I had 1 more articles in the media than Kaleido Biosciences. MarketBeat recorded 1 mentions for XIAO-I and 0 mentions for Kaleido Biosciences. XIAO-I's average media sentiment score of 1.89 beat Kaleido Biosciences' score of 0.00 indicating that XIAO-I is being referred to more favorably in the news media. Company Overall Sentiment Kaleido Biosciences Neutral XIAO-I Very Positive SummaryXIAO-I beats Kaleido Biosciences on 5 of the 7 factors compared between the two stocks. Get Kaleido Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for KLDO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding KLDO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KLDO vs. The Competition Export to ExcelMetricKaleido BiosciencesBiotechnology IndustryMedical SectorNASDAQ ExchangeMarket Cap$6.39M$130.34M$5.52B$9.32BDividend YieldN/A3.74%4.25%4.05%P/E Ratio0.003.5828.1519.68Price / SalesN/A4,239.34438.33100.29Price / CashN/A13.1935.5357.53Price / BookN/A42.048.235.67Net Income-$95.48M-$92.15M$3.23B$257.51M Kaleido Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KLDOKaleido BiosciencesN/AN/AN/AN/A$6.39M$1.10M0.0080AIXIXIAO-IN/A$1.96-3.0%N/AN/A$24.42M$70.31M0.00281Positive NewsSTIXSemantixN/AN/AN/AN/A$23.73M$264.23M0.004MTCMMTec1.1802 of 5 stars$0.95+3.1%N/A-69.7%$23.65M$1.87M0.0060MTBLYMoatableN/A$1.30+10.2%N/A+100.2%$23.17M$52.07M-13.00410STRMStreamline Health Solutions0.5079 of 5 stars$5.28-0.4%N/A-30.3%$23M$18.38M-2.32130XTKGX31.1608 of 5 stars$1.67-8.5%N/A-84.8%$22.84M$11.61M0.00200Positive NewsSMSISmith Micro Software4.5369 of 5 stars$1.06-6.2%$5.00+371.7%-55.7%$20.58M$20.56M-0.61370News CoverageHKITHitek Global0.6692 of 5 stars$1.42+0.7%N/A-9.6%$20.44M$2.90M0.0075Positive NewsMSGMMotorsport Games0.9768 of 5 stars$3.42+6.1%N/A+48.5%$19.85M$8.69M11.08190NTCLNetClass TechnologyN/A$1.27-2.3%N/AN/A$19.76M$10.10M0.0031News CoverageGap Down Related Companies and Tools Related Companies XIAO-I Competitors Semantix Competitors MMTec Competitors Moatable Competitors Streamline Health Solutions Competitors X3 Competitors Smith Micro Software Competitors Hitek Global Competitors Motorsport Games Competitors NetClass Technology Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:KLDO) was last updated on 7/16/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | Sponsored"Death Spiral" Threatening Your SavingsThe "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…GoldCo Precious Metals | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredTrump’s biggest move, misreportedThe media and financial pundits are all misreading Trump’s actions. They think Trump wants to make Canada t...Porter & Company | SponsoredIs this secretive Asian company trying to take over Bitcoin?A mysterious Asian conglomerate is buying billions in Bitcoin — but one legendary trader says that’s the wrong...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kaleido Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kaleido Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
